 0 Table of Contents |
  1 Clinical Practice Guidelines (CPG) on EBMonFHIR |
  2 Profiles |
  3 Code Systems |
  4 Value Sets |
  5 Extensions |
  6 Examples |
  7 Downloads |
  8 History |
  9 Artifacts Summary |
   9.1 Cohorts |
   9.2 CPGComputablePlanDefinition |
   9.3 CPGRecommendationDefinition |
   9.4 CPGShareablePlanDefinition |
   9.5 CPGStrategyDefinition |
   9.6 Eligibility Criteria |
   9.7 Outcome Evidence |
   9.8 PICO Evidence Variable |
   9.9 Recommendation Action |
   9.10 Shareable PlanDefinition |
   9.11 Assessment Action |
   9.12 Body Positioning Action |
   9.13 Certainty of Evidence Rating |
   9.14 Clinical Practice Guideline |
   9.15 Drug Administration Action |
   9.16 Evidence Data Set |
   9.17 Evidence Synthesis Cohorts |
   9.18 Guideline Bundle |
   9.19 Guideline Citation |
   9.20 Intervention Definition |
   9.21 Net Effect Estimate |
   9.22 Outcome Definition |
   9.23 Outcome Evidence Synthesis |
   9.24 Recommendation |
   9.25 Recommendation Citation |
   9.26 Recommendation Eligibility Criteria |
   9.27 Recommendation Justification |
   9.28 Recommendation Plan |
   9.29 Study Citation |
   9.30 Study Cohort |
   9.31 Study Eligibility Criteria |
   9.32 Study Outcome Evidence |
   9.33 Action Combination Method |
   9.34 ArtifactAssessment Publication Status |
   9.35 ArtifactAssessment Version |
   9.36 CQFM Artifact Comment |
   9.37 Dosage Condition |
   9.38 qualityOfEvidence |
   9.39 strengthOfRecommendation |
   9.40 Action Combination Method |
   9.41 Action Selection Behavior Required |
   9.42 Allergic Disposition SCT |
   9.43 Assessment |
   9.44 Assessment Scales |
   9.45 Body Positioning SNOMED CT |
   9.46 Clinical Importance of Outcome |
   9.47 Cochrane PICO |
   9.48 Cochrane PICO Intervention |
   9.49 Cochrane PICO Outcome |
   9.50 Cochrane PICO Population |
   9.51 Episode Of Care Type |
   9.52 Guideline Recommendation Status |
   9.53 Guideline Stage Classification |
   9.54 Laboratory Observations |
   9.55 Mean Difference Type |
   9.56 Observations SCT |
   9.57 Radiologic Finding SCT |
   9.58 Rating Acceptability |
   9.59 Rating Benefit And Harms |
   9.60 Rating Certainty Of Evidence |
   9.61 Rating Concern Degree |
   9.62 Rating Consensus |
   9.63 Rating Equity |
   9.64 Rating Feasibility |
   9.65 Rating Preference And Values |
   9.66 Rating Resources |
   9.67 Rating Up Rating One Level |
   9.68 Rating Up Rating Two Levels |
   9.69 Recommendation Strength |
   9.70 Relative Effect Type |
   9.71 Substances SNOMED CT |
   9.72 Ventilation Observable SCT |
   9.73 Action Combination Method |
   9.74 CEOsys Code System |
   9.75 Clinical Importance of Outcome |
   9.76 Cochrane Core Ontology |
   9.77 Cochrane PICO Ontology |
   9.78 Evidence Certainty Rating |
   9.79 Evidence To Decision Certainty Rating |
   9.80 Evidence To Decision Certainty type |
   9.81 Guideline Stage Classification |
   9.82 KontaktArtDe |
   9.83 Recommendation Strength |
   9.84 SynthesisType |
   9.85 All-cause mortality |
   9.86 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V |
   9.87 Certainty of Evidence for outcome: mortality of Dexamethasone application |
   9.88 COVID19 Intensive Care Treatment Guideline |
   9.89 COVID19 Intensive Care Treatment Guideline |
   9.90 Dexamethasone Application |
   9.91 Dexamethasone Application |
   9.92 Dexamethasone Application (Intravenous) |
   9.93 Dexamethasone Application (Oral) |
   9.94 Dexamethasone for critically ill COVID-19 patients |
   9.95 Dexamethasone Recommendation |
   9.96 Example Assessment Action |
   9.97 Example Body Positioning Action |
   9.98 Example Certainty Of Evidence Rating |
   9.99 Example DrugAdministration Action |
   9.100 Example Evidence Data Set |
   9.101 Example Evidence Synthesis Cohorts |
   9.102 Example Guideline |
   9.103 Example Guideline Citation |
   9.104 Example Intervention |
   9.105 Example Net Effect Estimate |
   9.106 Example No DrugAdministration Action |
   9.107 Example Organization |
   9.108 Example Outcome |
   9.109 Example Outcome Evidence Synthesis |
   9.110 Example Recommendation Citation |
   9.111 Example Recommendation Eligibility Criteria |
   9.112 Example Recommendation Justification |
   9.113 Example Recommendation plan |
   9.114 Example Study Citation |
   9.115 Example Study Cohort |
   9.116 Example Study Eligibility Criteria |
   9.117 Example Study Outcome Evidence |
   9.118 Guideline Recommendation Example |
   9.119 Mortality Outcome for Dexamethasone application |
   9.120 No Dexamethasone Application |
   9.121 No dexamethasone application for non-ventilated COVID-19 patients |
   9.122 NO Dexamethasone for moderately ill COVID-19 patients |
   9.123 Population: COVID19 Non-Ventilated |
   9.124 Population: COVID19 Ventilated |
   9.125 recommendation |
   9.126 Study cohort for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo) |
   9.127 Study eligibility criteria for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo) |
   9.128 Systemic corticosteroids for the treatment of COVID-19 |
   9.129 Therapy of hospitalized COVID-19 patients |